| 0000-00-00 |
|
|
|
External link to document |
| 2017-11-21 |
1 |
|
United States Patent Nos. 6,913,768 (“the
’768 patent”), 8,846,100 (“the ’100 patent”), and 9,173,857…(“Shire”), as the record
owner of U.S. Patent Nos. 6,913,768, 8,846,100, and 9,173,857.”
46.… This is a civil action for patent infringement arising under the patent laws of the
United States, …’857 patent”), attached hereto
as Exhibits A, B, and C, respectively (collectively, “the patents in suit…Plaintiff Shire LLC owns the ’768 patent.
38. The ’100 patent, entitled “Controlled Dose Drug |
External link to document |
| 2019-02-27 |
109 |
|
in U.S. Patent Nos.
6,913,768 ('"768 Patent"), 8,846,100 ("'100 Patent")…construction for multiple terms in U.S. Patent Nos. 6,913,768, 8,846,100, and 9,173,857. Within five days…claim 1 of the ' 100 Patent and claim 1 of
the ' 857 Patent. The Patents relate to "a long-acting…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to
which …construing patent claims, a court considers the literal language of
the claim, the patent specification |
External link to document |
| 2019-06-21 |
184 |
Notice of Service |
Invalidity Contentions for U.S. Patent No. 8,846,100 and U.S. Patent No. 9,173,857 filed by Actavis Laboratories…2017
8 November 2019
1:17-cv-01696
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |
| 2019-11-07 |
205 |
Patent/Trademark Report to Commissioner of Patents |
the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,913,768 B2; 8,846,100 B2; 9,173,857…2017
8 November 2019
1:17-cv-01696
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |
| 2017-11-21 |
4 |
|
the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,913,768 B2; 8,846,100 B2; 9,173,857…2017
8 November 2019
1:17-cv-01696
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |
